These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


588 related items for PubMed ID: 21385081

  • 21. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 22. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status.
    Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N, Yamashita S.
    Int J Cancer; 2007 Jan 01; 120(1):196-200. PubMed ID: 17044028
    [Abstract] [Full Text] [Related]

  • 23. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D, Qi W, Zhang P, Zhang Y, Liu Y, Guan H, Wang L.
    Pathol Res Pract; 2018 Feb 01; 214(2):303-307. PubMed ID: 29254799
    [Abstract] [Full Text] [Related]

  • 24. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F.
    J Clin Endocrinol Metab; 2008 Oct 01; 93(10):3943-9. PubMed ID: 18682506
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
    Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.
    Biomed Pharmacother; 2014 May 01; 68(4):413-7. PubMed ID: 24721322
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.
    Oncotarget; 2017 Jan 03; 8(1):900-914. PubMed ID: 27863429
    [Abstract] [Full Text] [Related]

  • 29. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL, Guo Y, Lyu YC, Nanding ZABYS, Gao WC, Shi TF, Qin HD, Liu SY.
    Zhonghua Zhong Liu Za Zhi; 2017 May 23; 39(5):361-366. PubMed ID: 28535653
    [Abstract] [Full Text] [Related]

  • 30. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD, Fu SS, Chen JY, Lee CH, Chau WK, Cheng CW, Wang YH, Lin YF, Fang WF, Tang KT.
    Thyroid; 2016 May 23; 26(5):691-704. PubMed ID: 26914762
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
    Paek SH, Kim BS, Kang KH, Kim HS.
    World J Surg Oncol; 2017 Nov 13; 15(1):202. PubMed ID: 29132392
    [Abstract] [Full Text] [Related]

  • 35. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S, Janković J, Marečko I, Išić Denčić T, Tatić S, Cvejić D, Savin S.
    Otolaryngol Head Neck Surg; 2014 Feb 13; 150(2):201-9. PubMed ID: 24255086
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 13; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 38. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY, Yoo JH, Park ES, Kim MK, Lee TJ, Cho BY, Chung YJ, Kang KH, Ahn HY, Kim HS.
    Pathol Res Pract; 2015 Feb 13; 211(2):162-70. PubMed ID: 25468810
    [Abstract] [Full Text] [Related]

  • 39. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.
    McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA.
    Pathology; 2013 Dec 13; 45(7):637-44. PubMed ID: 24247620
    [Abstract] [Full Text] [Related]

  • 40. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.
    Oncotarget; 2015 Dec 15; 6(40):42445-67. PubMed ID: 26636651
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 30.